Oxynorm ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 298 | Hereditary pancreatitis | 1 |
298. Hereditary pancreatitis
Clinical trials : 98 / Drugs : 180 - (DrugBank : 57) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-000732-34-DK (EUCTR) | 21/06/2017 | 25/04/2017 | Drug Release and Absorption from Controlled Release Formulations in Patients with Gastrointestinal Dysfunctions. | Oral Controlled Release Formulations to Patients with Gastrointestinal Dysfunction – Is the Release of Drug and the Absorption Impaired? - ABOXY | Healthy (pain) and patients (pain). MedDRA version: 20.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis;System Organ Class: 100000004856 MedDRA version: 20.0;Classification code 10012594;Term: Diabetes;System Organ Class: 100000004861 MedDRA version: 20.0;Classification code 10048516;Term: Gastrointestinal disorder (NOS);Classification code 10050554;Term: Gastric bypass NOS;System Organ Class: 100000004865 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Oxynorm Product Name: Oxynorm INN or Proposed INN: Oxycodone Other descriptive name: OXYCODONE Trade Name: Oxycodonhydrochlorid ”Lannacher”, depot tablets Product Name: Oxycodonhydrochlorid ”Lannacher”, depot tablets INN or Proposed INN: Oxycodone Other descriptive name: OXYCODONE HYDROCHLORIDE Trade Name: Oxycodone Depot ”Sandoz”, depot tablets Product Name: Oxycodone Depot ”Sandoz”, depot tablets INN or Proposed INN: Oxycodone Other descriptive name: OXYCODONE HYDROCHLORIDE | Mech-Sense, Dept. Gastroenterology & Hepatology, Aalborg University Hospital | NULL | Not Recruiting | Female: yes Male: yes | 135 | Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | Denmark |